Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094640
Status:
COMPLETED
Last Update Posted:
2006-07-19
First Post:
2004-10-21
Brief Title:
Pharmacokinetic Characterization of Intramuscular Olanzapine Depot
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goals of this study are to
Determine the blood levels of intramuscular IM olanzapine depot in patients at different points in time after an injection and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa olanzapine tablets or by intramuscular administration with Zyprexa IntraMuscular olanzapine for injection
Determine the blood levels of intramuscular IM olanzapine depot in patients at different points in time after an injection and compare these levels to the amount of olanzapine in the blood of patients after treated by oral administration with Zyprexa olanzapine tablets or by intramuscular administration with Zyprexa IntraMuscular olanzapine for injection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-EW-LOBS | None | None | None |